Bradmer Pharmaceutical’s novel compound, Neuradiab (previously referred to in literature as anti-tenascin radiolabled monoclonal antibody 131I-81C6), addresses one of the key weaknesses in the current therapy regimen for Glioblastoma Multiforme (GBM). GBM’s typically have infiltrating edges that are very difficult to remove surgically. Externally delivered radiation has limitations given the difficulty in focusing its energy specifically on remaining tumor cells and its potential to harm nearby sensitive and critical tissues. Neuradiab is a monoclonal antibody conjugated to radioactive iodine (I-131) that is delivered directly into the surgical resection cavity in a separate procedure following the initial surgery. Neuradiab’s molecular target is tenascin, a protein that is over-expressed by 99% of all GBM’s but is absent from normal brain tissues. Therefore, Neuradiab is able to deliver a concentrated level of radiation specifically to cancer cells that remain following surgical resection. In a series of Phase I and Phase II clinical trials completed to date, this methodology has been proven to be safe and effective, with encouraging Phase II data that show a significant increase in overall survival compared to currently approved therapies (see
Publications).
